Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis

Results from the treatment of early rheumatoid arthritis trial

Iris Navarro-Millán, Christina Charles-Schoeman, Shuo Yang, Joan M. Bathon, S. Louis Bridges, Lang Chen, Stacey S. Cofield, Louis J. Dell'Italia, Larry W. Moreland, James R. O'Dell, Harold E. Paulus, Jeffrey R. Curtis

Research output: Contribution to journalArticle

Abstract

Objective To study changes in lipid profiles at 24 weeks among patients with early rheumatoid arthritis (RA) participating in the Treatment of Early RA (TEAR) trial and randomized to receive methotrexate (MTX) plus etanercept, triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or aggressively titrated MTX monotherapy. Methods This TEAR substudy included 459 participants with biologic specimens. Serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol were measured at 0 and 24 weeks. Results At 24 weeks, there were statistically significant increases in mean cholesterol levels in the MTX plus etanercept, triple therapy, and MTX monotherapy arms. The observed increases were 31.4 mg/dl, 28.7 mg/dl, and 30 mg/dl in LDL cholesterol, 19.3 mg/dl, 22.3 mg/dl, and 20.6 mg/dl in HDL cholesterol, and 56.8 mg/dl, 53 mg/dl, and 57.3 mg/dl in total cholesterol (P <0.0001 versus baseline for each comparison). There was a statistically significant decrease in the ratio of total cholesterol to HDL cholesterol at 24 weeks in all 3 treatment groups versus baseline. There was no difference in any lipid changes between the 3 treatment arms. After multivariable adjustment, change in C-reactive protein, but not the Disease Activity Score in 28 joints, was associated with change in LDL cholesterol (P = 0.03) and total cholesterol (P = 0.01). Baseline glucocorticoid use was associated with changes in HDL cholesterol (P = 0.03) and total cholesterol (P = 0.02). Conclusion Levels of total cholesterol, LDL cholesterol, and HDL cholesterol increased comparably shortly after initiation of MTX plus etanercept, triple therapy, and MTX monotherapy among patients with early RA with active disease participating in a clinical trial. The clinical relevance of short-term changes in traditional lipids on cardiovascular outcomes remains to be determined.

Original languageEnglish (US)
Pages (from-to)1430-1438
Number of pages9
JournalArthritis and Rheumatism
Volume65
Issue number6
DOIs
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

Methotrexate
Lipoproteins
Rheumatoid Arthritis
Cholesterol
HDL Cholesterol
LDL Cholesterol
Lipids
Therapeutics
Hydroxychloroquine
Sulfasalazine
C-Reactive Protein
Glucocorticoids
Joints
Clinical Trials
Serum
Etanercept

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Rheumatology
  • Pharmacology (medical)

Cite this

Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis : Results from the treatment of early rheumatoid arthritis trial. / Navarro-Millán, Iris; Charles-Schoeman, Christina; Yang, Shuo; Bathon, Joan M.; Bridges, S. Louis; Chen, Lang; Cofield, Stacey S.; Dell'Italia, Louis J.; Moreland, Larry W.; O'Dell, James R.; Paulus, Harold E.; Curtis, Jeffrey R.

In: Arthritis and Rheumatism, Vol. 65, No. 6, 06.2013, p. 1430-1438.

Research output: Contribution to journalArticle

Navarro-Millán, I, Charles-Schoeman, C, Yang, S, Bathon, JM, Bridges, SL, Chen, L, Cofield, SS, Dell'Italia, LJ, Moreland, LW, O'Dell, JR, Paulus, HE & Curtis, JR 2013, 'Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: Results from the treatment of early rheumatoid arthritis trial', Arthritis and Rheumatism, vol. 65, no. 6, pp. 1430-1438. https://doi.org/10.1002/art.37916
Navarro-Millán, Iris ; Charles-Schoeman, Christina ; Yang, Shuo ; Bathon, Joan M. ; Bridges, S. Louis ; Chen, Lang ; Cofield, Stacey S. ; Dell'Italia, Louis J. ; Moreland, Larry W. ; O'Dell, James R. ; Paulus, Harold E. ; Curtis, Jeffrey R. / Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis : Results from the treatment of early rheumatoid arthritis trial. In: Arthritis and Rheumatism. 2013 ; Vol. 65, No. 6. pp. 1430-1438.
@article{7acf6e56113d43f2846ce1e3f89bcff7,
title = "Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: Results from the treatment of early rheumatoid arthritis trial",
abstract = "Objective To study changes in lipid profiles at 24 weeks among patients with early rheumatoid arthritis (RA) participating in the Treatment of Early RA (TEAR) trial and randomized to receive methotrexate (MTX) plus etanercept, triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or aggressively titrated MTX monotherapy. Methods This TEAR substudy included 459 participants with biologic specimens. Serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol were measured at 0 and 24 weeks. Results At 24 weeks, there were statistically significant increases in mean cholesterol levels in the MTX plus etanercept, triple therapy, and MTX monotherapy arms. The observed increases were 31.4 mg/dl, 28.7 mg/dl, and 30 mg/dl in LDL cholesterol, 19.3 mg/dl, 22.3 mg/dl, and 20.6 mg/dl in HDL cholesterol, and 56.8 mg/dl, 53 mg/dl, and 57.3 mg/dl in total cholesterol (P <0.0001 versus baseline for each comparison). There was a statistically significant decrease in the ratio of total cholesterol to HDL cholesterol at 24 weeks in all 3 treatment groups versus baseline. There was no difference in any lipid changes between the 3 treatment arms. After multivariable adjustment, change in C-reactive protein, but not the Disease Activity Score in 28 joints, was associated with change in LDL cholesterol (P = 0.03) and total cholesterol (P = 0.01). Baseline glucocorticoid use was associated with changes in HDL cholesterol (P = 0.03) and total cholesterol (P = 0.02). Conclusion Levels of total cholesterol, LDL cholesterol, and HDL cholesterol increased comparably shortly after initiation of MTX plus etanercept, triple therapy, and MTX monotherapy among patients with early RA with active disease participating in a clinical trial. The clinical relevance of short-term changes in traditional lipids on cardiovascular outcomes remains to be determined.",
author = "Iris Navarro-Mill{\'a}n and Christina Charles-Schoeman and Shuo Yang and Bathon, {Joan M.} and Bridges, {S. Louis} and Lang Chen and Cofield, {Stacey S.} and Dell'Italia, {Louis J.} and Moreland, {Larry W.} and O'Dell, {James R.} and Paulus, {Harold E.} and Curtis, {Jeffrey R.}",
year = "2013",
month = "6",
doi = "10.1002/art.37916",
language = "English (US)",
volume = "65",
pages = "1430--1438",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis

T2 - Results from the treatment of early rheumatoid arthritis trial

AU - Navarro-Millán, Iris

AU - Charles-Schoeman, Christina

AU - Yang, Shuo

AU - Bathon, Joan M.

AU - Bridges, S. Louis

AU - Chen, Lang

AU - Cofield, Stacey S.

AU - Dell'Italia, Louis J.

AU - Moreland, Larry W.

AU - O'Dell, James R.

AU - Paulus, Harold E.

AU - Curtis, Jeffrey R.

PY - 2013/6

Y1 - 2013/6

N2 - Objective To study changes in lipid profiles at 24 weeks among patients with early rheumatoid arthritis (RA) participating in the Treatment of Early RA (TEAR) trial and randomized to receive methotrexate (MTX) plus etanercept, triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or aggressively titrated MTX monotherapy. Methods This TEAR substudy included 459 participants with biologic specimens. Serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol were measured at 0 and 24 weeks. Results At 24 weeks, there were statistically significant increases in mean cholesterol levels in the MTX plus etanercept, triple therapy, and MTX monotherapy arms. The observed increases were 31.4 mg/dl, 28.7 mg/dl, and 30 mg/dl in LDL cholesterol, 19.3 mg/dl, 22.3 mg/dl, and 20.6 mg/dl in HDL cholesterol, and 56.8 mg/dl, 53 mg/dl, and 57.3 mg/dl in total cholesterol (P <0.0001 versus baseline for each comparison). There was a statistically significant decrease in the ratio of total cholesterol to HDL cholesterol at 24 weeks in all 3 treatment groups versus baseline. There was no difference in any lipid changes between the 3 treatment arms. After multivariable adjustment, change in C-reactive protein, but not the Disease Activity Score in 28 joints, was associated with change in LDL cholesterol (P = 0.03) and total cholesterol (P = 0.01). Baseline glucocorticoid use was associated with changes in HDL cholesterol (P = 0.03) and total cholesterol (P = 0.02). Conclusion Levels of total cholesterol, LDL cholesterol, and HDL cholesterol increased comparably shortly after initiation of MTX plus etanercept, triple therapy, and MTX monotherapy among patients with early RA with active disease participating in a clinical trial. The clinical relevance of short-term changes in traditional lipids on cardiovascular outcomes remains to be determined.

AB - Objective To study changes in lipid profiles at 24 weeks among patients with early rheumatoid arthritis (RA) participating in the Treatment of Early RA (TEAR) trial and randomized to receive methotrexate (MTX) plus etanercept, triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or aggressively titrated MTX monotherapy. Methods This TEAR substudy included 459 participants with biologic specimens. Serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol were measured at 0 and 24 weeks. Results At 24 weeks, there were statistically significant increases in mean cholesterol levels in the MTX plus etanercept, triple therapy, and MTX monotherapy arms. The observed increases were 31.4 mg/dl, 28.7 mg/dl, and 30 mg/dl in LDL cholesterol, 19.3 mg/dl, 22.3 mg/dl, and 20.6 mg/dl in HDL cholesterol, and 56.8 mg/dl, 53 mg/dl, and 57.3 mg/dl in total cholesterol (P <0.0001 versus baseline for each comparison). There was a statistically significant decrease in the ratio of total cholesterol to HDL cholesterol at 24 weeks in all 3 treatment groups versus baseline. There was no difference in any lipid changes between the 3 treatment arms. After multivariable adjustment, change in C-reactive protein, but not the Disease Activity Score in 28 joints, was associated with change in LDL cholesterol (P = 0.03) and total cholesterol (P = 0.01). Baseline glucocorticoid use was associated with changes in HDL cholesterol (P = 0.03) and total cholesterol (P = 0.02). Conclusion Levels of total cholesterol, LDL cholesterol, and HDL cholesterol increased comparably shortly after initiation of MTX plus etanercept, triple therapy, and MTX monotherapy among patients with early RA with active disease participating in a clinical trial. The clinical relevance of short-term changes in traditional lipids on cardiovascular outcomes remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=84878606005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878606005&partnerID=8YFLogxK

U2 - 10.1002/art.37916

DO - 10.1002/art.37916

M3 - Article

VL - 65

SP - 1430

EP - 1438

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 6

ER -